Lorsedin (Loratadine) 10mg

Indications and Dosage

Oral
Allergic conditions

Renal Impairment

CrCl (mL/min)	Dosage
<30	10 mg every other day.

Hepatic Impairment

Severe: Initially, 10 mg every other day.

Administration

May be taken with or without food.

Special Precautions

Severe hepatic and renal impairment. Children. Pregnancy and lactation.

Adverse Reactions

Significant: Headache, somnolence, drowsiness, fatigue, nervousness.
Cardiac disorders: Palpitation, tachycardia, hypotension.
Gastrointestinal disorders: Dry mouth, abdominal pain, nausea, vomiting, diarrhoea, gastritis.
General disorders and admin site conditions: Malaise.
Hepatobiliary disorders: Jaundice, hepatitis, hepatic necrosis.
Investigations: Elevated liver enzymes, weight gain.
Metabolism and nutrition disorders: Increased appetite.
Nervous system disorders: Dizziness.
Skin and subcutaneous tissue disorders: Rash, alopecia.

Patient Counseling Information

This drug may cause dizziness, if affected, do not drive or operate machinery.

Overdosage

Symptoms: Somnolence, tachycardia, drowsiness, headache. Management: Symptomatic and supportive treatment. May administer activated charcoal and may perform gastric lavage.

Drug Interactions

May increase plasma concentrations with ketoconazole, fluconazole, erythromycin, clarithromycin, cimetidine.

Food Interaction

Food delays time to peak plasma concentration and increases bioavailability. Increase risk of CNS depression with alcohol.

Lab Interference

May diminish the wheal and flare reactions to skin test antigens.

Action

Description: Loratadine, a piperidine derivative, is a long-acting, non-sedating antihistamine which selectively inhibits histamine H1-receptors on effector cells.
Onset: 1-3 hours.
Duration: >24 hours.
Pharmacokinetics:
Absorption: Rapidly and well absorbed from the gastrointestinal tract. Food delays time to peak plasma concentration and increases bioavailability. Time to peak plasma concentration: Approx 1-1.5 hours (loratadine); approx. 1.5-3.7 hours (desloratadine).
Distribution: Enters breast milk. Volume of distribution: 119 L/kg. Plasma protein binding: Approx 97-99% (loratadine); approx 73-76% (desloratadine).
Metabolism: Extensively undergoes first-pass metabolism in the liver via CYP2D6 and CYP3A4 to desloratadine as the active metabolite.
Excretion: Via urine (40%); faeces (approx 40% as metabolites). Elimination half-life: 8.4 hours (loratadine); 28 hours (desloratadine).